AHA In Brief
This article was originally published in The Gray Sheet
Medtronic PACE trial: Patients who received biventricular pacing with Medtronic's InSync III cardiac resynchronization therapy pacemaker (CRT-P) had no change in ejection fraction after one year, compared to a 6.8% reduction in ejection fraction for patients receiving right ventricular pacing alone, according to results of the Pacing to Avoid Cardiac Enlargement (PACE) trial presented Nov. 15 at the American Heart Association Scientific Sessions in Orlando. The data, which include 177 patients, were published online the same day in the New England Journal of Medicine. In addition, patients in the biventricular pacing group had no change in left ventricular size, while the right ventricular pacing arm saw a significant increase of 6.3 mL on average. Medtronic is also conducting the randomized, double-blind BLOCK-HF trial comparing biventricular and right ventricular pacing in heart failure patients with atrioventricular block; data on primary outcome measures are expected in late 2012. Biventricular pacing is currently not approved for pacemaker patients with normal pumping hearts, Medtronic notes
You may also be interested in...
Study results on ICD programming, biventricular pacing and more from the 2012 AHA Scientific Sessions in Los Angeles.
Abbott Vascular says it will approach FDA to design a U.S. clinical trial for its bioabsorbable everolimus-eluting stent once it gets data from a few hundred more patients in its overseas trials
Encouraging results on defibrillator survival rates and imaging-safe pacemakers, along with more detailed outcomes data from device replacements, were among the biggest take-away items from the Heart Rhythm Society's annual scientific sessions held in Boston earlier this month